Providing market research reports, industry analysis, company profiles and country reports for strategic planning, competitive intelligence, marketing and business research.
Search for Market Research Reports:    

China Anti-Diabetic Drug Market Report 2008

Published by: Draco Healthcare Consulting LLC

Published: Jan. 1, 2009 - 88 Pages


Table of Contents


CHAPTER I SUMMARY OF THE ANTI-DIABETIC DRUG MARKET

Section I: Overview of Diabetes in China

1.1 Diabetes and Its Classification

1.2 Diabetes Symptoms and Characteristics

1.3 Complications of Diabetes

1.4 Diabetes in China

Section 2: Summary of Anti-diabetic Drugs and their Classifications

2.1 Key Oral Anti-diabetic Drugs (Western Medicine)

2.2 TCM Blood-sugar Lowering Drugs

2.3 Insulin and Related Drugs

CHAPTER II SUMMARY OF THE GLOBAL ANTI-DIABETIC DRUG MARKET

Section 1: New Approvals of Anti-diabetic Drugs in 2007

Section 2: Summary of Global Anti-diabetic Drug Market

2.1 Global Market Sizes and Growth Rates of Anti-diabetic Drugs (2004-2007)

2.2 Anti-diabetic Drugs as the Top 5th Best Selling Category in 2007

2.3 Anti-diabetic Drugs Listed among the Top 50 Best Selling Drugs in 2006

2.4 Global Market Shares of Oral Anti-diabetic Drugs vs. Insulin and Insulin Analogs (2003-2007)

CHAPTER III ANALYSIS OF THE CHINESE ANTI-DIABETIC DRUG MARKET

Section 1 Sizes and Annual Growth Rates of the Chinese Anti-diabetic Drug Market (2002-2007)

1.1 Market Shares of Anti-diabetic Drugs by Category in China 2007

1.2 Market Sizes of Key Anti-diabetic Drugs by Category in China 2007

1.3 Sales and Manufacturers of the Top 10 Best Selling Oral Anti-diabetic Drugs in China 2007

1.4 Growth Forecast of China’s Anti-diabetic Drug Market by 2012

Section 2 Hospital Market Shares of Anti-diabetic Drug Manufacturers

2.1 Market Shares of the Top 20 Pharmaceutical Companies in the Chinese Anti-diabetic Drug Market (2005-2007)

2.2 Sales of the Top 20 Pharmaceutical Companies in the Chinese Anti-diabetic Drug Market (2005-2007)

2.3 Analysis of Market Concentration of the Top 4 and Top 8 Pharmaceutical Companies by Herfindahl-Hirschman Index

Section 3 Analysis of Hospital Market Shares and Annual Growth Rates of the Top 10 Best Selling Anti-diabetic Drugs in China (2005-2007)

CHAPTER IV MARKET SHARE ANALYSIS OF THE TOP 10 KEYANTI-DIABETIC DRUGS & COMPETITORS IN CHINA

Section 1: Manufacturers, Market Sizes and Shares for Insulin

Section 2: Manufacturers, Market Sizes and Shares for Acarbose

Section 3 Manufacturers, Market Sizes and Shares for Metformin

Section 4 Manufacturers, Market Sizes and Shares for Repaglinide

Section 5 Manufacturers, Market Sizes and Shares for Rosiglitazone

Section 6 Manufacturers, Market Sizes and Shares for Glipizide

Section 7: Manufacturers, Market Sizes and Shares for Gliquidone

Section 8 Manufacturers, Market Sizes and Shares for Gliclazide

Section 9 Manufacturers, Market Sizes and Shares for Nateglinide

Section 10 Manufacturers, Market Sizes and Shares for Xiaoke Wan (TCM Formulated)

CHAPTER V LIST OF BRAND NAMES, GENERIC NAMES, PRICES AND MANUFACTURERS OF ANTI-DIABETIC DRUGS IN CHINA & ANTI-DIABETIC DRUGS ON THE NATIONAL HEALTHCARE INSURANCE COVERAGE LIST

Section 1: Package, Unit, Retail Price of anti-diabetic Drugs and their Manufacturers in China

Section 2: Anti-diabetic Drugs on the National Healthcare Insurance and Work Injury Insurance List

2.1 Types of Insurance, Formula and Reimbursement Restriction

CHAPTER VI R& D OF ANTI-DIABETIC DRUGS

Section 1 Non-insulin Treatments for Type II Diabetes

1.1 Oral Anti-diabetic Drug as First Line Treatment

1.2 New Treatment Options: Incretin Treatment

1.3 Other Anti-diabetic Drugs under Phase II/III Clinical Studies

1.4 The US Market of Anti-diabetic Drugs

Section 2: Anti-diabetic Drugs Recently Approved or Currently under Clinical Study

2.1 Denmark’s Novo Nordisk Filed Regulatory Approval of its Type 2 Diabetes Drug Liraglutide in the US and Europe Simultaneously

2.2 New Anti-diabetic Drug Development by Eli Lilly and Transition

2.3 FDA Approved Novo Nordisk’s NovoLog for Treating Pediatric Diabetes Patients

2.4 FDA Accepted UCB’s NDA Application for Lacosamide for the Treatment of Adults with Diabetic Neuropathic Pain

2.5 US FDA Approved Amylin’s SymlinPen 120 and SymlinPen 60 Pen-injector Devices

CHAPTER VII GOVERNMENT POLICIES FOR THE CHINESE ANTI-DIABETIC DRUG MARKET

EXHIBITS

Table A Hospital Coverage for the Monitoring and Tracking of Drug Prescription and Purchasing Data in China

Table 1 Complication in Chinese Diabetes Patients

Table 2 DM and IGT Disease Rates (%) in Different BMI Populations

Table 3 Newly Approved Anti-diabetic Drug (New Molecule Entity) in 2007

Table 4 The Top 10 Best Selling Drug Categories in the World in 2007

Table 5 Anti-diabetic Drugs on the List of the World Top 50 Best Selling Drugs in 2006

Table 6 Sales of Anti-diabetic drugs by Categories in China 2007

Table 7 Top 10 Best Sellers of Oral Anti-diabetic Drugs in China 2007

Table 8 Market Shares of the Top 20 Pharmaceutical Companies in the Chinese Anti-diabetic Drug Hospital Market 2005-2007

Table 9 Sales of Anti-diabetic drugs of the Top 20 Pharmaceutical Companies in the Chinese Hospital Marekt 2005-2007

Table 10 Market Concentration Rates of the Chinese Anti-diabetic Drugs Hospital Market 2005 - 2007

Table 11 Market Shares and Growth Rates of the Top 10 Anti-diabetic drugs in China (2005-2007)

Table 12 Manufacturers, Market Sizes and Shares for Insulin (2006-2007)

Table 13 Sales of Insulin from the Top Pharmaceutical Companies in the Chinese Hospital Market 2006-2007

Table 14 Manufacturers, Market Sizes and Shares for Acarbose 2006-2007

Table 15 Sales of Acarbose from Top Pharmaceutical Companies in the Chinese Hospital Market 2007

Table 16 Manufacturers, Market Sizes and Shares for Metformin 2006-2007

Table 17 Sales of Metformin from the Top Pharmaceutical Companies in the Chinese Hospital Market 2006-2007

Table 18 Manufacturers, Market Sizes and Shares for Repaglinide 2006-2007

Table 19 Sales of Repaglinide from the Top Pharmaceutical Companies in the Chinese Hospital Market 2006-2007

Table 20 Manufacturers, Market Sizes and Shares for Rosiglitazone 2006-2007

Table 21 Sales of Rosiglitazone from the Top Pharmaceutical Companies in the Chinese Hospital Market 2006-2007

Table 22 Manufacturers, Market Sizes and Shares for Glipizide 2006-2007

Table 23 Sales of Glipizide from the Top Pharmaceutical Companies in the Chinese Hospital Market 2006-2007

Table 24 Manufacturers, Market Sizes and Shares for Gliquidone 2006-2007

Table 25 Sales of Gliquidone from the Top Pharmaceutical Companies in the Chinese Hospital Market 2007

Table 26 Manufacturers, Market Sizes and Shares for Gliclazide 2006-2007

Table 27 Sales of Gliclazide from the Top Pharmaceutical Companies in the Chinese Hospital Market 2006-2007

Table 28 Manufacturers, Market Sizes and Shares for Nateglinide 2006-2007

Table 29 Brand Names, Packages and Retail Prices of Anti-Diabetic Drugs and Their Manufacturers in China 2007

Table 30 Anti-diabetics of Western Medicine Covered by the National Basic Healthcare Insurance

Table 31 Anti-diabetics of Traditional Chinese Medicine (TCM) Covered by the National Basic Healthcare Insurance

Table 32 Anti-diabetic Drugs under Phase II/III Clinical Studies

Figure 1 Anti-diabetic Drugs in China

Figure 2 Global Market Sizes of Anti-diabetic Drugs (2004-2007)

Figure 3 Global Market Size of Oral Anti-diabetic Drugs and Insulin/Insulin Analogs

Figure 4 Sizes and Growth Rates of the Chinese Anti-diabetic Drug Market (2002-2007)

Figure 5 Market Shares of Different Anti-diabetic Drug Categories in China 2007

Figure 6 Market Sizes and Growth Rates of Xiaoke Wan 2005-2007

Figure 7 Sales vs. Prescription Volume of None-Insulin Anti-diabetic Drugs in United States (2006)

THE TOP 20 PHARMACEUTICAL COMPANIES IN THE CHINESE ANTI-DIABETIC DRUG MARKET (with at least > 0.57% of the China Anti-diabetic Drug Market in 2007)

Bayer

Beijing Liling Hengtai

Beijing Taiyang

Eli Lilly & Co

GlaxoSmithKline

Hangzhou Zhongmei Huadong Pharmaceutical Ltd.

Jiangsu Hangshen

Jiangsu Hengrui

Jiangsu Wangbang BioChem Co

Novartis

Novo Nordisk

Pfizer

sanofi-aventis

Servier (Tianjin)

Shanghai BMS

Taiji Group Chongqing Fuling Pharmaceutics

Takeda

Tonghua Dongbao

Wanhui Shanghe

Yangtze River

Abstract

Diabetes Mellitus (DM) is a chronic disease that occurs when the pancreas does not produce enough insulin, or alternatively, when the body cannot effectively use the insulin it produces.

When China started its economic reform in 1978, the diabetes disease rate was about 0.6% in the Chinese population. As China entered the rapid growth phase of its economic development, the diabetes disease rate has arisen rapidly. In 1995, the diabetes disease rate reached 1.5% and in 2000 the diabetic disease rate was 2.4% with the total number of diabetes patients at 31 million in China. The average addition of new diabetes patients each year was about 1.5 millions. Due to the increased numbers of diabetes patients and the improvements of living standards, the market size of anti-diabetic drugs has increased steadily in China. The market size of anti-diabetic drugs in 2002 was about RMB 4.187 billion and increased to RMB 7.495 billion in 2007 (USD 1.071 billion at 7:1 USD:RMB exchange rate) with an average annual growth of 13%. The annual growth rate from 2006 to 2007 was a significant 20.98%.

This report has systemically analyzed the Chinese anti-diabetic drug market. All drug data are based on hospital drug prescription and drug purchasing data from the hospital data monitor system that the China Nan Fang Institute of Medical and Economic Information has developed and maintained (Nan Fang Institute is a direct subsidiary of the Chinese State Food and Drug Administration SFDA). Sampled hospitals are from major Chinese cities across different geographic locations, including Beijing, Shanghai, Guangzhou, Nanjing, Chengdu, Chongqing, Xian, Shenyang, Harbin and Zhengzhou, covering significant percentages of all hospitals in these regions.

Market shares from all major players including multinational and Chinese pharmaceutical companies and their major anti-diabetics products are analyzed systemically based on data from significant number of Chinese hospitals. The comprehensive hospital utilization data of major anti-diabetic drugs will present you a clear picture of the competition landscape of Chinese anti-diabetics drug market and the market potential for your company's product(s) that already marketed in China or if you are planning to bring your drugs to the China market.

This China Anti-diabetic Drug Market Report has been indispensible references for all levels of decision makers in pharmaceutical companies, medical device companies, healthcare investing companies and healthcare consulting companies. These unique drug prescription and utilization data can provide valuable information for new product development, marketing and strategic planning functions for pharmaceutical companies. Compared to expensive customized drug reports in China, this multi-client report provides significant savings and great cost/benefit to pharmaceutical companies and interested parties.

Get Full Details About This Report >>
US: 800.298.5699
Int'l: +1.240.747.3093
Buy this Report
Price and Delivery Options
Search Inside Report


 

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 250,000 market research reports, company profiles and country profiles from over 650 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.

 

© MarketResearch.com 2009